For questions about BMS medicines during this time please call 1-800-721-8909.
IDHIFA® (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
FOR PATIENTS WHO HAVE R/R AML WITH AN IDH2 MUTATION
DISCOVER A TARGETED APPROACH
IDHIFA®: The first and only oral, targeted inhibitor of IDH2
NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY
(NCCN Guidelines®) recommend enasidenib (IDHIFA®) for R/R AML with an IDH2 mutation1
Eligibility
Patients must meet the following criteria to enroll:
Program Benefits
Program Timing
Additional Terms and Conditions of the Celgene Commercial Co-pay Programs
© 2017 Celgene Corporation 06/17 US-CELG170216